Clinical evaluation of Decitabine on the treatment of elderly patients with acute myeloid leukemia
10.3760/cma.j.issn.1008-6315.2016.08.013
- VernacularTitle:地西他滨治疗老年急性髓系白血病患者的临床评价
- Author:
Xueyun SHAN
;
Mo ZHOU
;
Xiaoli LI
;
Naitong SUN
- Publication Type:Journal Article
- Keywords:
Decitabine;
Acute myeloid leukemia;
Elderly
- From:
Clinical Medicine of China
2016;32(8):717-719
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical effect of Decitabine as the basis of the chemotherapy regimen on the treatment of elderly patients with acute myeloid leukemia( AML)?Methods The clinical data of elderly patients with AML admitted to the Third People ’ s Hospital of Yancheng from January 2013 to November 2015 were retrospective analyzed?The patients were divided into Decitabine group ( cases ) and the traditional group(19 cases) according to whether or not useed Decitabine,then evaluated the efficacy?Results The overall response rate( ORR) was 70?0% in 10 patients received decitabine,47?4% in 9 patents of the traditional group, and the difference was significant( P=0?03)?At the same time,the median survival time of the two groups was 44?87 months and 13?40 months respectively,the difference was statistically significant between the two groups (P=0?04)?There was no significant difference in the incidence of adverse reactions between the two groups ( granulocyte reduction, PLT reduction, fatigue, cardiovascular events, and respiratory tract infections ) ( P>0?05)?Conclusion The effect of Decitabine as the basis of the chemotherapy regimen on the treatment of AML is better,can prolong the survival time.
